Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | ZW171 |
| Synonyms | |
| Therapy Description |
ZW171 is a bispecific antibody targeting CD3 and mesothelin (MSLN), which potentially induces killing of tumor cells expressing MSLN and inhibits tumor growth (Cancer Res (2023) 83 (7_Supplement): 2942). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| ZW171 | MSLN Antibody 13 | ZW171 is a bispecific antibody targeting CD3 and mesothelin (MSLN), which potentially induces killing of tumor cells expressing MSLN and inhibits tumor growth (Cancer Res (2023) 83 (7_Supplement): 2942). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06523803 | Phase I | ZW171 | A Study of ZW171 in Participants With Advanced or Metastatic Mesothelin-expressing Cancers | Terminated | USA | GBR | DEU | 1 |